Johnson & Johnson (NYSE:JNJ) Announces Quarterly Earnings Results

Johnson & Johnson (NYSE:JNJ) posted its earnings results on Wednesday. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09, Zacks reports. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $2.82 earnings per share. Johnson & Johnson updated its FY 2025 guidance to 10.800-10.900 EPS.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $164.68 on Friday. The firm has a market capitalization of $396.24 billion, a price-to-earnings ratio of 17.59, a price-to-earnings-growth ratio of 2.21 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The firm has a fifty day moving average of $154.10 and a 200-day moving average of $154.84.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.16%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. UBS Group reaffirmed a “buy” rating and issued a $190.00 price target (up from $180.00) on shares of Johnson & Johnson in a research report on Thursday. Guggenheim raised their price target on shares of Johnson & Johnson from $164.00 to $167.00 and gave the stock a “neutral” rating in a research note on Thursday. Raymond James Financial cut their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday. Finally, Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday. Eleven research analysts have rated the stock with a hold rating, nine have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $174.11.

Hedge Funds Weigh In On Johnson & Johnson

An institutional investor recently raised its position in Johnson & Johnson stock. Brighton Jones LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 13.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 51,876 shares of the company’s stock after purchasing an additional 6,332 shares during the quarter. Brighton Jones LLC’s holdings in Johnson & Johnson were worth $7,502,000 as of its most recent SEC filing. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.